GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of why does nobody talk about appetite — 64 comments in the full submission. View in context.
6.4k
c/glp1science·submitted 1 year ago by u/lina_ndiaye

why does nobody talk about appetite

Explainerbranch of 7 comments

Genuine question, and the title is the question: why does nobody talk about appetite. Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random. Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the…

Read the full submission and all 64 comments →

This branch

7 comments, started 1 year ago
u/emil_agyeman965 points·1 year ago

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.

replysharereportpermalink
u/plain_titration280 points·1 year ago

a mechanism you can state is not a mechanism you have demonstrated

replysharereportpermalink
u/ferran_batista-21 points·1 year ago

half-life is why these are weekly and not daily

replysharereportpermalink
u/swirl_dont_shakereconstitution419 points·1 year ago

preclinical is not clinical and rodents are not small people

replysharereportpermalink
u/bastian_ekstrom190 points·1 year ago·edited

preclinical is not clinical and rodents are not small people

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

replysharereportpermalink
u/gastric_emptying_gMOD576 points·1 year ago

Left up and flaired Explainer. This is the standard of post the board was created for.

replysharereportpermalink
u/annika_fonseca265 points·1 year ago

dose response is not linear and nobody should assume it is

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.